University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Paul A. Volberding, MD

Paul A. Volberding, MD

Professor of Medicine, UCSF
Director, AIDS Research Institute
Director, Global Health Sciences Research
Co-Director, UCSF-GIVI Center for AIDS Research
Robert L. Weiss Memorial Chair for HIV/AIDS Research, UCSF

Cancer Center Program Memberships

Cancer Control

Research Summary

I was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. I have worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. I was the PI and co-director with Warner Greene of the NIAID-funded UCSF-Gladstone Center for AIDS Research supporting the large community of HIV investigators in San Francisco. CFAR provides core services, pilot grants to early career stage investigators and supports a comprehensive mentorship program. In the Clinical and Translational Sciences Institute I served as a member of the Board of Directors and formerly directed the Global Health Program. I stepped down as the Chief of the Medical Service at the San Francisco VA Medical Center in 2012 to become the Director of the UCSF AIDS Research Institute. The ARI is the comprehensive University organization that links all HIV/AIDS research programs and is the central focus for communications, media relations and philanthropic support for this internationally recognized response to the HIV epidemic. Recently, the ARI became the administrative home for a unique initiative to cure HIV infection funded by amfAR, the Foundation for AIDS Research. I serve as the Director of the amfAR Institute for HIV Cure, working with leading scientists at UCSF, the Gladstone Institute for Virology and Immunology, and the Vitalant (formerly the Blood Systems) Research Institute. I also served as the Associate Chair of the UCSF Department of Medicine for Global Health. My clinical appointment is at the VA as a retired volunteer physician where I maintain an active HIV outpatient practice. I am the Clinical Editor in Chief of the Journal of the Acquired Immunodeficiency Syndromes and served as the Chair of the Scientific Advisory Board of the Accordia Global AIDS Foundation and the Infectious Diseases Institute at Makerere University in Kampala Uganda. I was a board member of the Pangaea Global AIDS Foundation. I am an active member of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academy of Sciences and am the founder and Board Chair of the International Antiviral Society-USA. On Twitter I am @pvolberding.


University of Chicago, BA, 1967-1971, Biology
University of Minnesota, MD, 1971-1975, Medicine
University of Utah Medical Center, Residency, 1975-1978, Internal Medicine
University of California San Francisco, Fellow, 1978-1981, Hematology/Oncology

Professional Experience

  • 1968-1971
    Virology Laboratory Assistant, Dr. Marc Beem, University of Chicago
  • 1971-1975
    University of Minnesota School of Medicine
    Avian type C virus receptor research, Dr. Charles Moldow
  • 1975-1978
    Medicine Internship and Residency, University of Utah Medical Center, Salt Lake City
  • 1978-1979
    Clinical Fellow in Hematology/Oncology, University of California, San Francisco
    Clinical research conducted with Dr. Michael Friedman on therapy of hepatic tumors
  • 1979-1981
    Research Fellow in Hematology/Oncology, University of California, San Francisco
    Research conducted in the laboratory of Dr. Jay A. Levy studying mechanisms controlling infection with xenotropic type C retroviruses
  • 1981-1986
    Assistant Professor of Medicine, University of California, San Francisco
  • 1981-present
    Chief, Medical Oncology Division, San Francisco General Hospital
  • 1984-present
    Director, AIDS Program, San Francisco General Hospital
  • 1986-1990
    Associate Professor of Medicine, University of California, San Francisco
  • 1988-present
    Director, Center for AIDS Research, University of California, San Francisco
  • 1990-present
    Professor of Medicine, University of California, San Francisco
  • 1994-present
    Full Member, Cancer Center, University of California, San Francisco
  • 1997
    Program Leader, HIV Malignancies Research Program, UCSF Comprehensive Cancer Center
  • 2001-present
    Vice Chair, Department of Medicine, University of California, San Francisco
  • 2001-present
    Chief of the Medical Service, San Francisco Veterans Affairs Medical Center

Honors & Awards

  • 1986-1987
    National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee
  • 1986-1987
    American Medical Association AIDS Panel
  • 1986-1988
    NIH AIDS Drug Selection Committee Member
  • 1986-1988
    National Institutes of Allergy and Infectious Disease AIDS Clinical Trials Group Executive Committee
  • 1987-1990
    National Academy of Sciences (Institute of Medicine) AIDS Activities Oversight Committee
  • 1990-1992
    International AIDS Society, President
  • 1992-1993
    Co-chair Institute of Medicine Round Table on AIDS Drug and Vaccine Development
  • 1993-present
    Founder and Board Chair, International AIDS Society - USA, Inc.
  • 1994-present
    National Policy Advisory Board for the HIV Cost and Services Utilization Study, RAND
  • 1997-present
    HIV Research Agenda Committee, AIDS Clinical Trials Group
  • 1998-present
    Interim Review Committee, ACTG 372
  • 1998-present
    Interim Review Committee, ACTG 368
  • 1998-present
    Center for AIDS Research Directors' Group, Chair
  • 1999-present
    Institute of Medicine

Selected Publications

  1. Harding BN, Whitney BM, Nance RM, Ruderman SA, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis. 2020 Mar 20; 20(1):238.
    View on PubMed
  2. Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open. 2020 Mar 19; 10(3):e031487.
    View on PubMed
  3. Heinemann AW, Volberding PA. National Academies Consensus Report on Functional Assessment for Adults With Disabilities. Arch Phys Med Rehabil. 2019 Dec; 100(12):2407-2408.
    View on PubMed
  4. Volberding P, Chambers HF. Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. JAMA Intern Med. 2019 Nov 11.
    View on PubMed
  5. Kang M, Grund B, Hunsberger S, Glidden D, Volberding P. Interim monitoring in a treatment strategy trial with a composite primary endpoint. Contemp Clin Trials. 2019 Nov; 86:105846.
    View on PubMed
  6. Satre DD, Anderson AN, Leibowitz AS, Levine-Hall T, Slome S, Flamm J, Hare CB, McNeely J, Weisner CM, Horberg MA, Volberding P, Silverberg MJ. Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial. Contemp Clin Trials. 2019 Sep; 84:105833.
    View on PubMed
  7. Scott H, Volberding PA. HIV Screening and Preexposure Prophylaxis Guidelines: Following the Evidence. JAMA. 2019 06 11; 321(22):2172-2174.
    View on PubMed
  8. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, Horberg M, Volberding P, Silverberg MJ. Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial. J Gen Intern Med. 2019 Oct; 34(10):2054-2061.
    View on PubMed
  9. Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis. 2019 Jan; 6(1):ofy353.
    View on PubMed
  10. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View on PubMed
  11. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
    View on PubMed
  12. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396.
    View on PubMed
  13. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).
    View on PubMed
  14. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151.
    View on PubMed
  15. Malekinejad M, Parriott A, Blodgett JC, Horvath H, Shrestha RK, Hutchinson AB, Volberding P, Kahn JG. Effectiveness of community-based condom distribution interventions to prevent HIV in the United States: A systematic review and meta-analysis. PLoS One. 2017; 12(8):e0180718.
    View on PubMed
  16. Volberding PA. How to Survive a Plague: The Next Great HIV/AIDS History. JAMA. 2017 04 04; 317(13):1298-1299.
    View on PubMed
  17. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Top Antivir Med. 2017 Feb/Mar; 25(1):17-24.
    View on PubMed
  18. Volberding P, Blattner WA. JAIDS: Transitions, Evolution, and Impact. J Acquir Immune Defic Syndr. 2017 01 01; 74(1):1-2.
    View on PubMed
  19. Satre DD, Altschuler A, Parthasarathy S, Silverberg MJ, Volberding P, Campbell CI. Implementation and Operational Research: Affordable Care Act Implementation in a California Health Care System Leads to Growth in HIV-Positive Patient Enrollment and Changes in Patient Characteristics. J Acquir Immune Defic Syndr. 2016 Dec 15; 73(5):e76-e82.
    View on PubMed
  20. Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, Volberding P, Tucker JD. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016 09 20; 16:994.
    View on PubMed

Go to UCSF Profiles, powered by CTSI